Alnylam Pharmaceuticals, founded in 2002 and headquartered in Cambridge, Massachusetts, is the world's leading RNA interference (RNAi) therapeutics company. Its work is centered on a revolutionary approach to medicine: silencing the genes that cause illness. The company operates in the biopharmaceutical and biotechnology sectors, with commercial operations spanning multiple continents and a team of more than 1,900 employees globally.
The company's core technical domains are RNA interference, genetic medicine, and biopharmaceutical development. Its therapeutic pipeline is focused on both rare and common diseases, including conditions such as TTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria.
Alnylam describes its culture as award-winning and notes its ability to attract talent dedicated to changing the future of medicine. The company's scientific focus places it at the forefront of a significant shift in how diseases may be treated.
